U.S., March 8 -- ClinicalTrials.gov registry received information related to the study (NCT06865339) titled 'Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer' on March 04.
Brief Summary: Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
NSCLC
Locally Advanced
Intervention:
DRUG: Cemiplimab
Human IgG anti-PD-1 monoclonal antibody approved for treatment of advanced NSCLC with PD-L1 TPS >= 50% as monotherapy...